In patients with treatment-sensitive cancers, does systemic anti-cancer therapy increase the chance of malignant pleural effusion control?

N. Holling (Bristol, United Kingdom), S. Patole (Bristol, United Kingdom), A. Medford (Bristol, United Kingdom), N. Maskell (Bristol, United Kingdom), A. Bibby (Bristol, United Kingdom)

Source: Virtual Congress 2020 – Novel directions in pleural disease: bench to bedside
Session: Novel directions in pleural disease: bench to bedside
Session type: E-poster session
Number: 1141
Disease area: Thoracic oncology

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
N. Holling (Bristol, United Kingdom), S. Patole (Bristol, United Kingdom), A. Medford (Bristol, United Kingdom), N. Maskell (Bristol, United Kingdom), A. Bibby (Bristol, United Kingdom). In patients with treatment-sensitive cancers, does systemic anti-cancer therapy increase the chance of malignant pleural effusion control?. 1141

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: